Cellona Therapeutics, Inc. Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant for CT-10 Novel Targeted Cancer Compound
"We are pleased that our innovative molecular targeted approach and CT-10's potential as a novel treatment for various cancers have been recognized by this grant award," said Brad Fackler, Chief Executive Officer of Cellona Therapeutics. "Our company is appreciative of this additional source of non-dilutive capital to advance potential new targeted therapies to treat cancer and address unmet medical needs."
The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer.
About Cellona Therapeutics
Cellona Therapeutics, Inc. is a privately held pharmaceutical company developing and commercializing targeted therapeutics to improve survival paradigms in cancer patients. Our oncology compounds target novel signaling pathways, and have potential indications in large therapeutic markets with considerable unmet needs. Cellona Therapeutics is developing a new class of cancer drug to inhibit the RAS family of cancer proteins. Mutation and hyperactivity of RAS family members occurs in, and is a driver of, most human cancers. Our compounds offer selective inhibition of these onco-proteins that mediate and control cancer genesis and growth. For more information visit http://www.cellonatherapeutics.com
Contact: Cellona Therapeutics, Inc. Wendy Tsai, Vice President, tsaiw@cellonatherapeutics.com.